Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO

Philipp Harter, Jalid Sehouli, Alexander Reuss, Annette Hasenburg, Giovanni Scambia, David Cibula, Sven Mahner, Ignace Vergote, Alexander Reinthaller, Alexander Burges, Lars Hanker, Martin Pölcher, Christian Kurzeder, Ulrich Canzler, Karl Ulrich Petry, Andreas Obermair, Edgar Petru, Barbara Schmalfeldt, Domenica Lorusso, Andreas Du Bois

Research output: Contribution to journalArticle

Abstract

Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trialwas planned to verify this hypothesis prospectively in a multicenter setting. Methods: Participating centers prospectively enrolled all consecutive patients with platinumsensitive first or second relapse. The score was applied to all patients, but centers were free to decide on therapy. All further therapies were documented, and the outcome of patients was analyzed. A 75% complete resection rate in 110 prospectively classified patients had to be achieved to confirm a positive predictive value of 2 or higher of 3 with 95% probability. Results: Atotal of 516 patientswere screened within 19 months; of these, 261 patients (51%) were classified as score positive, and 129 patients with a positive score and first relapse were operated on. The rate of complete resection was 76%, thus confirming the validity of this score regarding positive prediction of complete resectability in 2 or more of 3 patients. Complication rates were moderate including second operations in 11% and perioperative mortality in 0.8%. Conclusions: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2011

Keywords

  • AGO score
  • Recurrent ovarian cancer
  • Surgery ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO'. Together they form a unique fingerprint.

  • Cite this

    Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. U., Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., & Du Bois, A. (2011). Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer, 21(2), 289-295. https://doi.org/10.1097/IGC.0b013e31820aaafd